Taken together, our data suggest that the RBM4high/ LKB1low expression defines glutamine metabolic reprogramming and confer increased sensitivity of ESCC cells to glutaminase inhibition, providing a novel potential target for ESCC therapeutics. This evidence concerns the gene GLS and esophageal squamous cell carcinoma.